Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov

Rhea-AI Filing Summary

10x Genomics, Inc. reported that Chief Executive Officer Serge Saxonov acquired an equity award in the form of restricted stock units covering 157,895 shares of Class A Common Stock at a stated price of $0.00 per share on February 26, 2026.

Each RSU represents a right to receive one share of Class A Common Stock upon vesting. According to the terms, 1/12 of the RSUs vest on each quarterly anniversary starting from February 21, 2026, as long as he continues as a service provider on each vesting date.

The filing also lists indirect holdings of Class A Common Stock held by the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust, for which Saxonov serves as trustee, totaling separate positions of 27, 213,250, and 58,000 shares respectively.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/26/2026		A		157,895(1)	A	$0	1,219,819	D
Class A Common Stock								27	I	See footnote(2)
Class A Common Stock								213,250	I	See footnote(3)
Class A Common Stock								58,000	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

2. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

3. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

4. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did 10x Genomics (TXG) CEO Serge Saxonov report on this Form 4?

Serge Saxonov reported receiving a grant of restricted stock units covering 157,895 shares of 10x Genomics Class A Common Stock. The award was recorded at a stated price of $0.00 per share and is subject to a multi-year vesting schedule.

How many 10x Genomics (TXG) shares are covered by the new RSU grant?

The new RSU grant covers 157,895 shares of 10x Genomics Class A Common Stock. Each unit converts into one share upon vesting, providing potential future share ownership as vesting conditions tied to continued service are met over time.

What is the vesting schedule for Serge Saxonov’s 10x Genomics (TXG) RSUs?

The RSUs vest in equal quarterly installments, with 1/12 of the units vesting on each quarterly anniversary from February 21, 2026. Vesting requires Serge Saxonov to continue as a service provider to 10x Genomics on each applicable vesting date.

Did Serge Saxonov buy or sell 10x Genomics (TXG) shares in the market?

The Form 4 shows an acquisition through a grant of restricted stock units, not an open-market purchase or sale. The transaction code is A, indicating a grant or award, with a price of $0.00 per share rather than a market transaction.

What indirect 10x Genomics (TXG) holdings did Serge Saxonov report?

Serge Saxonov reported indirect holdings of Class A Common Stock held by three trusts: Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust. These positions total 27, 213,250, and 58,000 shares, respectively, with Saxonov serving as trustee for each trust.

How many 10x Genomics (TXG) shares does Serge Saxonov hold directly after this grant?

After the RSU grant, Serge Saxonov’s direct holdings of 10x Genomics Class A Common Stock are reported as 1,219,819 shares. This figure excludes additional indirect holdings reported through various trusts for which he serves as trustee.